Daniel Jake Hoyle

Dr. Daniel Jake Hoyle

School of Pharmacy and Pharmacology, University of Tasmania, Hobart, Tasmania, Australia
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 November 2023 in Journal of the American Geriatrics Society
Verified
Journal Article
Open access
AAArmando Silva Almodóvar
Armando Silva Almodóvar
MKMichelle S. Keller
Michelle S. Keller
JLJiha Lee
Jiha Lee
HMHemalkumar B. Mehta
Hemalkumar B. Mehta
VMVeena Manja
Veena Manja
ALAmy M. Linsky
Amy M. Linsky
Deprescribing is the intentional dose reduction or discontinuation of a medication. The development of deprescribing interventions should take into consideration important organizational, interprofessional, and patient‐specific barriers that can be further complicated by the presence of multiple prescribers involved in a patient's care. Patients who receive care from an increasing number of prescribers may experience disruptions in the timely transfer of relevant healthcare information, increasing the risk of exposure to drug–drug interactions and other medication‐related problems. Furthermore, the fragmentation of healthcare information across health systems can contribute to the refilling of discontinued medications, reducing the effectiveness of deprescribing interventions. Thus, deprescribing interventions must carefully consider the unique characteristics of patients and their prescribers to ensure interventions are successfully implemented. In this special article, an international working group of physicians, pharmacists, nurses, epidemiologists, and researchers from the United States Deprescribing Research Network (USDeN) developed a socioecological model to understand how multiple prescribers may influence the implementation of a deprescribing intervention at the individual, interpersonal, organizational, and societal level. This manuscript also includes a description of the concept of multiple prescribers and outlines a research agenda for future investigations to consider. The information contained in this manuscript should be used as a framework for future deprescribing interventions to carefully consider how multiple prescribers can influence the successful implementation of the service and ensure the intervention is as effective as possible.

27 January 2018 in Drugs & Aging
Verified
Journal Article
Closed access
PDF file
Daniel Jake HoyleDaniel Jake Hoyle
Daniel Jake Hoyle
IBIvan Bindoff
Ivan Bindoff
LCLisa M. Clinnick
Lisa M. Clinnick
Gregory PetersonGregory Peterson
Gregory Peterson
JWJuanita L. Westbury
Juanita L. Westbury

2 October 2023 in International Psychogeriatrics
Verified
Journal Article
Open access
PDF file
MAMustafa Atee
Mustafa Atee
CBClaire V. Burley
Claire V. Burley
VOVictor Adekola Ojo
Victor Adekola Ojo
AAAgboola Jamiu Adigun
Agboola Jamiu Adigun
HLHayoung Lee
Hayoung Lee
tomas leontomas leon
tomas leon
The International Psychogeriatric Association (IPA) has expressed significant concerns over the use of physical restraints in older people across diverse aged care settings. Following an extensive analysis of the available literature, the IPA’s Early Career Network (ECN) has formulated a collection of evidence-based recommendations aimed at guiding the use of physical restraints within various care contexts and demographic groups. Physical restraints not only infringe upon human rights but also raise significant safety concerns that adversely impact the physical, psychological, social, and functional well-being of older adults. Furthermore, their effectiveness in geriatric settings remains inadequate. Given these considerations, the IPA and its ECN firmly assert that the use of physical restraints should only be considered as a final recourse in the care of older people.

1 June 2021 in International Psychogeriatrics
Verified
Journal Article
Open access
Daniel Jake HoyleDaniel Jake Hoyle
Daniel Jake Hoyle
GPGregory M. Peterson
Gregory M. Peterson
IBIvan K. Bindoff
Ivan K. Bindoff
LCLisa M. Clinnick
Lisa M. Clinnick
ABAidan D. Bindoff
Aidan D. Bindoff
JBJuanita Louise Breen
Juanita Louise Breen
To explore the relationships between dose changes to antipsychotic and/or benzodiazepine medications and resident outcomes, including variations in neuropsychiatric symptoms, quality of life (QoL), and social withdrawal, within a multicomponent, interdisciplinary antipsychotic and benzodiazepine dose reduction program. Prospective, observational, longitudinal study. The Reducing Use of Sedatives (RedUSe) project involved 150 Australian Long-Term Care Facilities (LTCFs) incorporating auditing and benchmarking of prescribing, education, and multidisciplinary sedative reviews. A convenience sample of LTCFs (n = 28) involved in RedUSe between January 2015 and March 2016. Permanent residents (n = 206) of LTCFs involved in RedUSe taking an antipsychotic and/or benzodiazepine daily. Residents were excluded if they had a severe psychiatric condition where antipsychotic therapy should generally be maintained long-term (e.g., bipolar disorder, schizophrenia) or were considered end-stage palliative. Neuropsychiatric symptoms (Neuropsychiatric Inventory, Cohen-Mansfield Agitation Inventory (CMAI)), QoL (Assessment of Quality of Life-4D), and social withdrawal (Multidimensional Observation Scale for Elderly Subjects-withdrawal subscale) were measured at baseline and 4 months where nursing staff completed psychometric tests as proxy raters. There was no evidence that psychometric measures were worsened following dose reductions. In fact, dose reduction was associated with small, albeit non-statistically significant, improvements in behavior, particularly less physically non-aggressive behavior with both drug groups (-0.36 points per 10% reduction in antipsychotic dose, -0.17 per 10% reduction in benzodiazepine dose) and verbally agitated behavior with benzodiazepine reduction (-0.16 per 10% dose reduction), as measured with the CMAI. Furthermore, antipsychotic reduction was associated with non-statistically significant improvements in QoL and social withdrawal. Antipsychotic and benzodiazepine dose reduction in LTCFs was not associated with deterioration in neuropsychiatric symptoms, QoL, or social withdrawal. Trends toward improved agitation with antipsychotic and benzodiazepine dose reduction require further evaluation in larger, prospective, controlled studies.

24 November 2024 in American Journal of Cardiovascular Drugs
Verified
Journal Article
Closed access
PDF file
AZAmirreza Zobdeh
Amirreza Zobdeh
Daniel Jake HoyleDaniel Jake Hoyle
Daniel Jake Hoyle
PSPankti Shastri
Pankti Shastri
WBWoldesellassie M. Bezabhe
Woldesellassie M. Bezabhe
Gregory PetersonGregory Peterson
Gregory Peterson

19 October 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AZAmirreza Zobdeh
Amirreza Zobdeh
Gregory PetersonGregory Peterson
Gregory Peterson
WBWoldesellassie M. Bezabhe
Woldesellassie M. Bezabhe
PSPankti Shastri
Pankti Shastri
Daniel Jake HoyleDaniel Jake Hoyle
Daniel Jake Hoyle
Background/Objectives: Atrial fibrillation (AF), the most common cardiac arrhythmia, significantly elevates the risk of new-onset heart failure (HF). We aimed to systematically map and appraise available evidence on drug therapies and incident HF in patients with AF. Methods: We searched Medline, Embase, Cochrane Central Register of Controlled Trials, and Scopus up to 16 September 2026 for relevant randomized controlled trials (RCTs), sub-analyses of RCTs, and observational/cohort studies. Results: Seventeen studies (397,991 participants) were included. The only randomized signal came from a prespecified subgroup of the ACTIVE-I trial, in which irbesartan was associated with fewer first HF hospitalizations than the placebo (HR 0.81, 95% CI 0.69–0.96; moderate certainty). Observational studies showed an association with lower first HF hospitalization for sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients with type 2 diabetes (pooled HR 0.68, 95% CI 0.48–0.95; two studies; low certainty) and lower incident HF diagnosis in a larger cohort that included patients without diabetes (HR 0.86, 95% CI 0.82–0.89). The remaining cohort evidence largely reflected prescribing patterns rather than drug effects. Statins showed an inconsistent association. The higher HF incidence among users of diuretics, mineralocorticoid receptor antagonists, digoxin and renin-angiotensin system inhibitors was consistent with confounding by indication (very low certainty). Conclusions: Evidence on drug therapies to prevent HF in AF is limited to one randomized subgroup signal for irbesartan. The remaining findings were associations rather than demonstrated treatment effects. High-quality research, including RCTs in broader AF populations, is needed. PROSPERO Registration: CRD42024587926.